Maurizio Zangari

List of Publications by Year in Descending Order

181 papers	5,583 citations	31 h-index	74 g-index
188 ext. papers	6,328 ext. citations	4 avg, IF	4.7 L-index

#	Paper	IF	Citations
181	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.. *American Journal of Hematology*, **2022**,	7.1	
180	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	3
179	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.. *JAMA Network Open*, **2022**, 5, e228161	10.4	1
178	Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience.. *American Journal of Hematology*, **2022**,	7.1	1
177	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. *Blood*, **2021**, 138, 2713-2713	2.2	
176	N-Cadherin Stabilizes □Catenin and Promotes □Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. *Blood*, **2021**, 138, 1572-1572	2.2	
175	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. *Blood*, **2021**, 138, 566-566	2.2	0
174	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. *Blood*, **2021**, 138, 1627-1627	2.2	
173	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. *Blood Advances*, **2021**,	7.8	4
172	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. *Blood*, **2021**, 138, 4110-4110	2.2	0
171	Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. *Bone*, **2021**, 146, 115876	4.7	3
170	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. *Journal of Clinical Oncology*, **2021**, 39, e20031-e20031	2.2	1
169	Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. *American Journal of Hematology*, **2021**, 96, E341-E344	7.1	3
168	High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. *British Journal of Haematology*, **2021**, 195, 283-286	4.5	2
167	PHF19 inhibition as a therapeutic target in multiple myeloma. *Current Research in Translational Medicine*, **2021**, 69, 103290	3.7	3
166	Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. *European Journal of Haematology*, **2021**, 106, 230-240	3.8	5
165	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. *Nature Communications*, **2021**, 12, 293	17.4	20

164	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	3
163	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. *Haematologica*, **2021**, 106, 3215-3218	6.6	0
162	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. *Leukemia*, **2021**,	10.7	3
161	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. *Blood Cancer Journal*, **2020**, 10, 70	7	16
160	Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma?. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e551-e555	2	
159	and Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 2422-2432	12.9	17
158	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. *Blood*, **2020**, 136, 44-44	2.2	1
157	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. *Blood*, **2020**, 136, 2-2	2.2	
156	Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT. *Blood*, **2020**, 136, 24-24	2.2	
155	An Improved Animal Model of Multiple Myeloma Bone Disease. *Blood*, **2020**, 136, 31-31	2.2	
154	CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction. *Blood*, **2020**, 136, 21-21	2.2	
153	Late Relapsing Multiple Myeloma ≥10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. *Blood*, **2020**, 136, 11-12	2.2	2
152	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. *Blood Advances*, **2020**, 4, 181-190	7.8	5
151	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. *Journal of Clinical Oncology*, **2020**, 38, 8514-8514	2.2	2
150	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. *PLoS Medicine*, **2020**, 17, e1003323	11.6	10
149	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. *British Journal of Haematology* , **2020**, 189, 67-71	4.5	20
148	Innate Biomineralization. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
147	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. *Journal of Hematology and Oncology*, **2020**, 13, 108	22.4	8

146	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. *Blood Advances*, **2020**, 4, 422-431	7.8	30
145	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. *Transplant Infectious Disease*, **2019**, 21, e13052	2.7	4
144	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. *Blood Cancer Journal*, **2019**, 9, 62	7	17
143	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. *Theranostics*, **2019**, 9, 4756-4763	12.1	7
142	A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. *Cell Transplantation*, **2019**, 28, 1624-1631	4	
141	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. *Blood*, **2019**, 134, 4333-4333	2.2	2
140	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. *Blood*, **2019**, 134, 4569-4569	2.2	2
139	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. *Blood*, **2019**, 134, 4412-4412	2.2	
138	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. *Blood*, **2019**, 134, 3309-3309	2.2	1
137	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. *Blood*, **2019**, 134, 508-508	2.2	
136	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. *Blood*, **2019**, 134, 4379-4379	2.2	
135	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. *Blood*, **2019**, 134, 4390-4390	2.2	
134	Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients. *Blood*, **2019**, 134, 5638-5638	2.2	
133	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. *Bone*, **2019**, 121, 134-138	4.7	1
132	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. *British Journal of Haematology*, **2019**, 184, 578-593	4.5	11
131	Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. *British Journal of Haematology*, **2019**, 184, 308-310	4.5	2
130	Kinase domain activation through gene rearrangement in multiple myeloma. *Leukemia*, **2018**, 32, 2435-2444	10.7	15
129	Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma. *Journal of Bone Oncology*, **2018**, 12, 19-22	4.5	1

128	Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice. *Endocrinology*, **2018**, 159, 1561-1569	4.8	1
127	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. *Clinical Cancer Research*, **2018**, 24, 2913-2919	12.9	17
126	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. *Haematologica*, **2018**, 103, 1047-1053	6.6	29
125	Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging. *Biomaterials*, **2018**, 183, 67-76	15.6	24
124	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. *Blood*, **2018**, 132, 110-110	2.2	1
123	Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies. *Blood*, **2018**, 132, 1882-1882	2.2	2
122	The Mutational Landscape of Primary Plasma Cell Leukemia. *Blood*, **2018**, 132, 114-114	2.2	2
121	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. *Blood*, **2018**, 132, 408-408	2.2	2
120	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. *Blood*, **2018**, 132, 4457-4457	2.2	
119	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. *Blood*, **2018**, 132, 4441-4441	2.2	
118	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. *Blood*, **2018**, 132, 4465-4465	2.2	1
117	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. *Blood*, **2018**, 132, 4468-4468	2.2	
116	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. *Blood*, **2018**, 132, 3185-3185	2.2	
115	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. *Blood*, **2018**, 132, 1906-1906	2.2	
114	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. *Blood*, **2018**, 132, 4471-4471	2.2	
113	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. *Blood*, **2018**, 132, 4448-4448	2.2	
112	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. *Blood*, **2018**, 132, 4489-4489	2.2	0
111	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. *Blood*, **2018**, 132, 1929-1929	2.2	

110	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. *Blood*, **2018**, 132, 59-66	2.2	43
109	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. *Journal of Bone and Mineral Research*, **2017**, 32, 1261-1266	6.3	5
108	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. *Haematologica*, **2017**, 102, e313-e316	6.6	21
107	The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma. *Haematologica*, **2017**, 102, e364-e367	6.6	44
106	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. *American Journal of Hematology*, **2017**, 92, 739-745	7.1	21
105	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. *Clinical Cancer Research*, **2017**, 23, 2665-2672	12.9	9
104	Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. *Clinical Cancer Research*, **2017**, 23, 1981-1987	12.9	57
103	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. *Immunotherapy*, **2016**, 8, 367-84	3.8	4
102	The effects of proteasome inhibitors on bone remodeling in multiple myeloma. *Bone*, **2016**, 86, 131-8	4.7	29
101	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. *Blood*, **2016**, 128, 2065-2065	2.2	1
100	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. *Blood*, **2016**, 128, 3266-3266	2.2	1
99	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. *Blood*, **2016**, 128, 3278-3278	2.2	2
98	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. *Blood*, **2016**, 128, 3304-3304	2.2	2
97	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. *Blood*, **2016**, 128, 377-377	2.2	1
96	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. *Blood*, **2016**, 128, 4431-4431	2.2	7
95	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. *Blood*, **2016**, 128, 4516-4516	2.2	8
94	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. *Blood*, **2016**, 128, 117-117	2.2	1
93	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. *Blood*, **2016**, 128, 2064-2064	2.2	

92	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. *Blood*, **2016**, 128, 4416-4416	2.2	0
91	Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models. *Blood*, **2016**, 128, 5664-5664	2.2	0
90	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. *Blood*, **2016**, 128, 4438-4438	2.2	
89	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. *Blood*, **2016**, 128, 115-115	2.2	2
88	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. *Blood*, **2016**, 128, 1735-44	2.2	129
87	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. *Blood*, **2015**, 125, 3756-9	2.2	31
86	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). *Haematologica*, **2015**, 100, 1214-21	6.6	34
85	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. *Blood*, **2015**, 126, 1806-1806	2.2	1
84	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. *Blood*, **2015**, 126, 1808-1808	2.2	1
83	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). *Blood*, **2015**, 126, 1843-1843	2.2	1
82	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. *Blood*, **2015**, 126, 20-20	2.2	4
81	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. *Blood*, **2015**, 126, 2979-2979	2.2	2
80	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. *Blood*, **2015**, 126, 369-369	2.2	1
79	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. *Blood*, **2015**, 126, 372-372	2.2	1
78	Thymus-Derived PTH (TPTH) Is Increased after Thyroparathyroidectomy in C57BL6/Kalwrij Mice and Modulates Mouse Sensitivity to 5TGM1 Myeloma Cell Line. *Blood*, **2015**, 126, 5335-5335	2.2	1
77	Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts). *Blood*, **2015**, 126, 1997-1997	2.2	
76	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. *Blood*, **2015**, 126, 724-724	2.2	
75	Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma. *Blood*, **2015**, 126, 2982-2982	2.2	

74	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. *Blood*, **2015**, 126, 4173-4173	2.2	
73	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. *Blood*, **2015**, 126, 3181-3181	2.2	
72	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. *Blood*, **2015**, 126, 3182-3182	2.2	
71	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). *Blood*, **2015**, 126, 5395-5395	2.2	
70	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. *Blood*, **2015**, 126, 4193-4193	2.2	
69	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. *Blood*, **2014**, 123, 2504-12	2.2	33
68	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. *Bone*, **2014**, 61, 39-43	4.7	10
67	Curing Multiple Myeloma (MM) with Total Therapy (TT). *Blood*, **2014**, 124, 195-195	2.2	3
66	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). *Blood*, **2014**, 124, 2128-2128	2.2	0
65	Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience. *Blood*, **2014**, 124, 2999-2999	2.2	2
64	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. *Blood*, **2014**, 124, 3409-3409	2.2	1
63	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. *Blood*, **2014**, 124, 3418-3418	2.2	3
62	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. *Blood*, **2014**, 124, 4775-4775	2.2	4
61	Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma. *Blood*, **2014**, 124, 725-725	2.2	1
60	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. *Blood*, **2014** , 124, 2079-2079	2.2	
59	Surgical Control/Cure of 5TGM1 Murine Multiple Myeloma Model By Thyroparathyroidectomy. *Blood*, **2014**, 124, 3387-3387	2.2	
58	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. *Blood*, **2014**, 124, 2078-2078	2.2	
57	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. *Blood*, **2014**, 124, 3407-3407	2.2	

56	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. *Blood*, **2014**, 124, 5770-5770	2.2	
55	NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. *Cancer Cell*, **2013**, 23, 48-62	24.3	178
54	Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?. *Blood Coagulation and Fibrinolysis*, **2013**, 24, 311-6	1	17
53	Impact of bortezomib on bone health in myeloma: a review of current evidence. *Cancer Treatment Reviews*, **2012**, 38, 968-80	14.4	38
52	Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 768-79	5.3	11
51	Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies. *Blood*, **2012**, 120, 4073-4073	2.2	1
50	Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 228-36	2	51
49	Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. *Blood Coagulation and Fibrinolysis*, **2011**, 22, 420-3	1	3
48	A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. *Haematologica*, **2011**, 96, 333-6	6.6	45
47	Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. *European Journal of Haematology*, **2011**, 86, 484-7	3.8	33
46	Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. *Journal of Clinical Oncology*, **2010**, 28, 132-5	2.2	49
45	Thrombotic events in patients with cancer receiving antiangiogenesis agents. *Journal of Clinical Oncology*, **2009**, 27, 4865-73	2.2	167
44	The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. *American Journal of Hematology*, **2009**, 84, 6-14	7.1	120
43	Bleeding disorders associated with cancer dysproteinemias. *Cancer Treatment and Research*, **2009**, 148, 295-304	3.5	4
42	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. *British Journal of Haematology*, **2008**, 141, 433-44	4.5	28
41	Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. *British Journal of Haematology*, **2007**, 137, 530-6	4.5	40
40	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. *British Journal of Haematology*, **2007**, 138, 176-85	4.5	262
39	Thrombosis in multiple myeloma. *Expert Review of Anticancer Therapy*, **2007**, 7, 307-15	3.5	48

38	Hemostatic dysfunction in paraproteinemias and amyloidosis. *Seminars in Thrombosis and Hemostasis*, **2007**, 33, 339-49	5.3	55
37	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood*, **2007**, 109, 2276-84	2.2	699
36	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. *Blood Coagulation and Fibrinolysis*, **2007**, 18, 595-8	1	19
35	Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.. *Blood*, **2007**, 110, 548-548	2.2	2
34	Stroke in a Multiple Myeloma Cohort.. *Blood*, **2007**, 110, 4772-4772	2.2	
33	Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. *Current Pharmaceutical Biotechnology*, **2006**, 7, 449-53	2.6	4
32	The molecular classification of multiple myeloma. *Blood*, **2006**, 108, 2020-8	2.2	824
31	Response to bortezomib and activation of osteoblasts in multiple myeloma. *Clinical Lymphoma and Myeloma*, **2006**, 7, 109-14		40
30	A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. *Blood*, **2006**, 108, 111-111	2.2	3
29	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. *Blood*, **2006**, 108, 3393-3393	2.2	1
28	Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. *Haematologica*, **2006**, 91, 192-9	6.6	119
27	Anticoagulation regimens for thalidomide and lenalidomide. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 658-9	0.6	1
26	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. *British Journal of Haematology*, **2005**, 131, 71-3	4.5	169
25	Immunomodulatory drugs in multiple myeloma. *Expert Opinion on Investigational Drugs*, **2005**, 14, 1411-8	5.9	14
24	Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).. *Blood*, **2005**, 106, 3490-3490	2.2	2
23	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.. *Blood*, **2005**, 106, 423-423	2.2	5
22	The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.. *Blood*, **2005**, 106, 510-510	2.2	2
21	Serum Concentrations of Vitamin B-12 and Alkaline Phosphatase in Newly Diagnosed Multiple Myeloma Patients.. *Blood*, **2005**, 106, 5110-5110	2.2	

20	Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.. *Blood*, **2005**, 106, 1981-1981	2.2	
19	Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.. *Blood*, **2005**, 106, 1152-1152	2.2	
18	Acquired Resistance to Activated Protein C (aAPCR) Is Associated with Increased Risk of Deep Vein Thrombosis in Multiple Myeloma.. *Blood*, **2005**, 106, 3484-3484	2.2	
17	The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.. *Blood*, **2005**, 106, 1157-1157	2.2	
16	Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs Discontinuous Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).. *Blood*, **2005**, 106, 1153-1153	2.2	
15	Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. *Clinical Cancer Research*, **2004**, 10, 88-95	12.9	98
14	Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).. *Blood*, **2004**, 104, 1480-1480	2.2	24
13	Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.. *Blood*, **2004**, 104, 2884-2884	2.2	2
12	Protective Effect of VELCADE on Thalidomide-Associated Deep Vein Thrombosis (DVT).. *Blood*, **2004**, 104, 4914-4914	2.2	5
11	Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.. *Blood*, **2004**, 104, 77-77	2.2	16
10	Addition of Bortezomib (Velcade) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. *Blood*, **2004**, 104, 929-929	2.2	10
9	Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).. *Blood*, **2004**, 104, 940-940	2.2	
8	Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.. *Blood*, **2004**, 104, 934-934	2.2	
7	Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).. *Blood*, **2004**, 104, 4935-4935	2.2	
6	The blood coagulation mechanism in multiple myeloma. *Seminars in Thrombosis and Hemostasis*, **2003**, 29, 275-82	5.3	66
5	Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. *Clinical Lymphoma and Myeloma*, **2003**, 4, 32-5		91
4	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. *Blood*, **2002**, 99, 1745-57	2.2	534
3	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. *Blood*, **2001**, 98, 492-4	2.2	474

2	Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. *British Journal of Haematology*, **2001**, 114, 600-7	4.5	165
1	Results of autologous stem cell transplant in multiple myeloma patients with renal failure. *British Journal of Haematology*, **2001**, 114, 822-9	4.5	212